Traws Pharma advances flu and COVID-19 antiviral pipeline

Traws Pharma ( (TRAW) ) has provided an announcement.

On January 13, 2026, Traws Pharma filed a U.S. Investigational New Drug application with the FDA for tivoxavir marboxil (TXM), a potential best-in-class, single-dose oral CAP-dependent endonuclease inhibitor for the treatment of seasonal and avian influenza, a move that represents the final step toward formal consideration by BARDA for inclusion in the U.S. strategic national stockpile. In a separate update from an ongoing randomized Phase 2 trial in mild-to-moderate COVID-19, the company reported interim data in 50 patients showing that ratutrelvir, its ritonavir-free oral 3CL protease inhibitor, delivered faster sustained symptom resolution than PAXLOVID, no observed viral or symptom rebound events, fewer adverse effects and favorable tolerability, including in PAXLOVID-ineligible patients at higher risk of severe disease, reinforcing Traws’ bid to position ratutrelvir as a next-generation COVID-19 therapy and to expand its role in both acute treatment and potential long-COVID prevention strategies.

The most recent analyst rating on (TRAW) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Spark’s Take on TRAW Stock

According to Spark, TipRanks’ AI Analyst, TRAW is a Neutral.

The score is held back primarily by weak financial performance (minimal revenue, widening losses, rising cash burn, and negative equity), indicating high funding risk. Technicals remain bearish with price below major moving averages, though oversold signals provide some counterbalance. Positive clinical and strategy-related corporate updates add upside potential but do not outweigh current financial pressures.

To see Spark’s full report on TRAW stock, click here.

More about Traws Pharma

Traws Pharma, Inc. (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company focused on developing novel oral antiviral therapies targeting critical respiratory viral threats, including SARS-CoV-2/COVID-19 and influenza. Its pipeline includes ratutrelvir, a ritonavir-free Mpro/3CL protease inhibitor for COVID-19, and tivoxavir marboxil (TXM), a single-dose CAP-dependent endonuclease inhibitor candidate for seasonal and avian influenza, aimed at both commercial treatment markets and government stockpiling and pandemic-preparedness programs.

Average Trading Volume: 370,592

Technical Sentiment Signal: Sell

Current Market Cap: $10.71M

Learn more about TRAW stock on TipRanks’ Stock Analysis page.